Literature DB >> 3300968

Cardiotoxicity of 5-fluorouracil.

C Collins, P L Weiden.   

Abstract

Three patients developed anterior substernal chest pain in association with ischemic electrocardiographic changes temporally related to continuous infusions of 5-fluorouracil (5-FU). Two patients developed myocardial infarctions and one died. Cardiac toxicity of 5-FU may be more likely when the drug is given by continuous infusion in the presence of preexisting cardiac disease. The pattern of cardiac toxicity suggests cardiac ischemia most likely secondary to coronary artery vasospasm. Patients should not receive 5-FU by infusion if they have significant underlying coronary artery disease or if they develop anterior substernal chest pain while receiving the drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300968

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  11 in total

1.  5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study.

Authors:  J A Casas; P A Saway; I Villarreal; C Nolte; B L Menajovsky; E E Escudero; W D Blackburn; G S Alarcón; C P Subauste
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Concomitant radiochemotherapy with 5-FU and cisplatin for invasive bladder cancer. Acute toxicity and first results.

Authors:  S Birkenhake; S Leykamm; P Martus; R Sauer
Journal:  Strahlenther Onkol       Date:  1999-03       Impact factor: 3.621

Review 4.  Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.

Authors:  Kelly C Gast; Paul V Viscuse; Somaira Nowsheen; Tufia C Haddad; Robert W Mutter; Andrea E Wahner Hendrickson; Fergus J Couch; Kathryn J Ruddy
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-01

5.  Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor.

Authors:  A von Herbay; B Dörken; G Mall; M Körbling
Journal:  Klin Wochenschr       Date:  1988-12-01

Review 6.  Cardiotoxicity of the antiproliferative compound fluorouracil.

Authors:  K Becker; J F Erckenbrecht; D Häussinger; T Frieling
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 7.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 8.  Cancer chemotherapy in older adults. A tolerability perspective.

Authors:  G G Kimmick; R Fleming; H B Muss; L Balducci
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

Review 9.  Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.

Authors:  Michael E Layoun; Chanaka D Wickramasinghe; Maria V Peralta; Eric H Yang
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

Review 10.  Vascular toxic effects of cancer therapies.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-26       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.